The Emerging Markets business continues Lilly’s legacy to deliver innovative medicines that address unmet needs and has a profound impact on people’s lives around the world. More than 6,000 employees in 30 Lilly affiliates work across the 70 countries that make up Lilly’s Emerging Markets business.
Lilly’s Unique Emerging Markets
With a well-balanced and diversified portfolio, the Emerging Markets business is driven with clear strategic choices in mind, and begins with establishing the “right footprint” of Lilly innovation, emphasizing strengths in diabetes, oncology and neuroscience. Diabetes is the highest priority therapeutic area across all geographies with the evolution of the disease. The Emerging Markets business area is experiencing a higher underlying growth as Lilly brings much needed medications to these countries. These factors combined will bring forth a significant share of global market growth.
We will build Lilly's business for tomorrow, today
Lilly’s Emerging Markets business is building for tomorrow by serving the unique needs of its patients today. This can only be accomplished by understanding what our customers truly value and providing exceptional customer experiences, every day. Emerging Markets is committed to be a strong advocate for patients and to deliver the best possible healthcare outcomes.